Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Murilo Barato Agudo Romão"'
Autor:
André Mattar, Murilo Barato Agudo Romão, Luiz Henrique Gebrim, Guilherme Ribeiro Fonseca, Debbie M Jakubowski, Maria C S Bastos, Maria Antonieta Longo Galvão Silva, Monica Maria Agata Stiepcich, Sergio C Oliveira, Fabio Bagnoli, José Francisco Rinaldi, Jorge Yoshinori Shida, Calvin Chao, Vilmar Marques de Oliveira
Publikováno v:
JCO Global Oncology
PURPOSE We evaluated the impact of 21-gene test results on treatment decisions for patients with early-stage breast cancer treated under the public health care system in Brazil, Sistema Único de Saúde. METHODS Eligible patients treated at Hospital
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a828facd7ec6db251075fb4cc77027a
https://doi.org/10.1200/go.20.00609
https://doi.org/10.1200/go.20.00609
Autor:
Murilo Barato Agudo Romão, André Mattar, Jorge Yoshinori Shida, Roberto Hegg, Guilherme Ribeiro Fonseca
Publikováno v:
Mastology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d73f65ab16618deb82d23aa194791c22
https://doi.org/10.29289/259453942019v29s1g05
https://doi.org/10.29289/259453942019v29s1g05
Autor:
Murilo Barato Agudo Romão, Calvin Chao, Debbie M Jakubowski, Sergio C Oliveira, Jorge Yoshinori Shida, Guilherme Ribeiro Fonseca, Luiz Henrique Gebrim, André Mattar
Publikováno v:
Journal of Clinical Oncology. 38:e19380-e19380
e19380 Background: Selecting appropriate patients for AC (adjuvant chemotherapy) remains an important issue in BC treatment. Although AC improves clinical outcomes toxicity and economic burden is substantial. The Oncotype DX test identifies high-risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7313cf7a56125caaa8757cf4a824554f
https://doi.org/10.1200/jco.2020.38.15_suppl.e19380
https://doi.org/10.1200/jco.2020.38.15_suppl.e19380
Autor:
Monica Maria Agata Stiepcich, Calvin Chao, Murilo Barato Agudo Romão, André Mattar, Debbie M Jakubowski, Luiz Henrique Gebrim, Guilherme Ribeiro Fonseca, Jorge Yoshinori Shida, Sergio C Oliveira
Publikováno v:
Journal of Clinical Oncology. 38:e12518-e12518
e12518 Background: The 21-gene assay estimates risk of recurrence expressed as a Recurrence Score result between 0 and 100. The assay is clinically validated to predict chemotherapy (CT) benefit in node-negative (N0) and node-positive (up to three ax
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72adf1ca31cc7b22d736bcdc6e2e75e2
https://doi.org/10.1200/jco.2020.38.15_suppl.e12518
https://doi.org/10.1200/jco.2020.38.15_suppl.e12518